View Author
Sibbles, B.
( B. Sibbles)
patient disease glucosidase treatment muscle pompe disease 4 patients pompe enzyme rhaglu month study rabbit glycogen therapy rotterdam glucosidase activity 40 mg /kg enzyme replacement therapy rabbit milk production 20 mg /kg development activity storage infant netherland alpha-glucosidase mutation muscle function 4 years protein erasmus mc-sophia function 1 year 12 weeks reuser aj baseline lysosomal fabry disease patient 3 van der ploeg infusion erasmu motor 110- kda precursor tissue efficacy inclusion effect reuser patients 1 erasmus mc department quadriceps muscle patient 1 hypertrophy acid alpha-glucosidase 3 months number pediatrics replacement ventilator 37 months phase lysosomal acid alpha-glucosidase glycogenosis type ii animal j hum genet pompe disease fig j biol chem change genet method hum mol genet 2 years fabry glucosidase gene muscle strength patient 4
1 Most Recent Publications
|
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk
(Article)
Hout, J.M.P. van den Sibbles, B. Corven, E.J. van Hirtum, H. van Kamphoven, J.H.J. Ploeg, A.T. van der Hove, J. van Arts, W.F.M. Doorn, P.A. van Klerk, J.B. de Loonen, M.C.B. Vulto, A.G. Brakenhoff, J.P. Kroos, M.A. Hop, W.C.J. Winkel, L.P.F. Jong, G. de Cromme-Dijkhuis, A.H. Weisglas-Kuperus, N. Reuser, A.J.J. Boer, M. Smeitink, J.A. Diggelen, O.P. van Voort, E. van der |
2004-01-01
|